Quick Fix Summary: For drug approval in the EU, use the European Medicines Agency (EMA). For medical device approval, apply for a CE Mark through a notified body. For food safety, rely on EFSA. FDA approval is not automatically valid in Europe.
What's Happening
In Europe, drug and medical product regulation works differently than in the U.S.
Here’s the thing: the European Union doesn’t have a single agency like the FDA. Instead, it uses a decentralized system where national regulators team up with the European Medicines Agency (EMA). The EMA handles the science, but the European Commission makes the final call. For medical devices, you’ll need a CE Mark from a notified body—not a single regulator like the FDA.
What’s the European equivalent of the FDA?
Honestly, this is the best way to think about it: the EMA coordinates evaluations, but the European Commission signs off on approvals. For medical devices, there’s no single equivalent—you work with notified bodies to get your CE Mark. Food safety? That’s the European Food Safety Authority (EFSA).
How does EU drug approval compare to the FDA’s process?
EU drug approval involves the EMA’s scientific review followed by a European Commission decision, while the FDA handles both science and final approval in one agency.
In most cases, the FDA acts as both the scientist and the decision-maker. The EU splits those roles. The EMA’s committees (like CHMP for human medicines) do the technical review, then send their opinion to the Commission, which issues the actual approval. That’s why EU timelines often feel longer—they include this extra step.
What’s the fastest way to get medicine approved in the EU?
Use the EMA’s accelerated assessment, which cuts review time to 150 days instead of the standard 210.
If your product qualifies (usually for serious conditions with no existing treatments), the PRIME scheme can speed things up even more. That said, don’t expect miracles—even accelerated reviews take months. Plan for at least five months from submission to approval.
Which EU procedure should I use for my medicine?
Use the Centralized Procedure for EU-wide approval, or the Decentralized/Mutual Recognition Procedures for single-country or limited coverage.
Here’s the breakdown:
- Centralized: One application, one approval covering all EU countries. Required for biologics, advanced therapies, and orphan drugs.
- Decentralized: You apply in one country first, then expand to others. Good if you only need a few markets.
- Mutual Recognition: If you already have approval in one EU country, other countries can recognize it without re-reviewing your whole application.
How do medical devices get approved in the EU?
Manufacturers must obtain a CE Mark through a notified body, with risk class determining how rigorous the process is.
Class I devices (low risk) can often self-certify. But if your device is Class IIa, IIb, or III? You’ll need a notified body to review your technical documentation. Once approved, you affix the CE Mark and register in EUDAMED. The rules got stricter under the new Medical Device Regulation (MDR)—so if your device was approved under the old system, you’ll likely need to re-certify.
What’s the difference between FDA 510(k) and EU CE Mark?
The 510(k) is a U.S. premarket notification for moderate-risk devices, while the CE Mark is an EU conformity assessment covering all risk classes.
That’s a key difference. In the U.S., a 510(k) shows your device is “substantially equivalent” to existing ones. In the EU, the CE Mark proves your device meets safety and performance standards—regardless of whether similar devices already exist. Also, the CE Mark process is generally more paperwork-heavy, especially for higher-risk devices.
How does EFSA compare to the FDA’s food regulation role?
EFSA provides scientific risk assessments, while the European Commission makes final authorization decisions—similar to how the FDA operates but with separate roles.
EFSA doesn’t approve foods or additives directly. Instead, it evaluates safety, then passes its opinion to the Commission, which makes the actual authorization call. The FDA, by contrast, handles both science and decisions under one roof. If you’re submitting a novel food or additive application, expect EFSA’s review to take around six months—sometimes longer if they request more data.
What happens if my EU application gets rejected?
You can appeal the decision within 60 days or switch to a different regulatory procedure if your product’s scope changes.
First, don’t panic. The EMA’s CHMP or CVMP will give you detailed reasons for the rejection. You can request a re-examination, but you’ll need strong new data or arguments to overturn the decision. Another option? Adjust your application strategy. Maybe the Centralized Procedure isn’t working—try the Mutual Recognition route instead. And honestly, early conversations with regulators can prevent these issues in the first place.
How can I avoid common EU regulatory mistakes?
Engage early with the EMA or national agencies, monitor regulation updates, and budget for fees that vary by company size.
Start early—like, during drug development. The EMA’s Scientific Advice Working Party (SAWP) can guide you before you even file your application. Stay on top of regulation changes too; the EU pharmaceutical rules and MDR get updated often. And don’t forget fees: small companies pay around €15,000 for EMA reviews, while big pharma can shell out €300,000. Plan accordingly.
What fees should I expect for EU regulatory approval?
Can I use my FDA approval to get EU approval?
No, FDA approval doesn’t automatically grant EU market access—you’ll still need to go through EU regulatory pathways.
That said, having FDA approval can help. The EMA might accept some of your existing data, especially if your product was approved under similar standards. But don’t assume it’ll be a smooth process. The EU often requires additional studies or documentation. If you’re thinking of repurposing an FDA-approved drug for the EU market, plan for extra time and costs.
How long does EU drug approval typically take?
Standard reviews take about 210 days, while accelerated assessments can wrap up in 150 days.
But here’s the catch: those timelines only cover the EMA’s scientific review. The European Commission adds another 60–120 days to issue the final decision. So realistically, expect 9–12 months from submission to market access. For generics or biosimilars, it’s usually faster—around 6–9 months. And if you’re unlucky enough to face a rejection, add another 6–12 months for appeals and resubmissions.
What’s the role of national agencies in EU approvals?
National agencies handle local reviews, post-market surveillance, and sometimes additional country-specific requirements beyond EMA or EFSA assessments.
Think of them as the local enforcers. For example, Germany’s BfArM or France’s ANSM might require extra data even after EMA approval. They also monitor safety once your product hits the market. If you’re targeting just one or two countries, engaging with their agencies early can save headaches later. And for veterinary products? The EMA’s CVMP handles evaluations, but individual countries can still impose their own rules.
Where can I find official EU regulatory guidance?
These sites are your best friends. The EMA’s pages break down procedures, fees, and timelines for medicines. The European Commission’s medical device section covers MDR implementation. And EFSA’s portal has everything from novel food guidance to additive safety assessments. Pro tip: bookmark the “Regulatory Roadmaps” sections—they’re gold for planning your submission timeline.
Edited and fact-checked by the TechFactsHub editorial team.
David Okonkwo David Okonkwo holds a PhD in Computer Science and has been reviewing tech products and research tools for over 8 years. He's the person his entire department calls when their software breaks, and he's surprisingly okay with that.
